NCT06747390View on ClinicalTrials.gov

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2028

Conditions
Oropharyngeal Squamous Cell Carcinoma (OPSCCA)Oropharyngeal CancerHuman Papilloma VirusSquamous Cell Carcinoma
Interventions
DRUG

Lidocaine 1% Injectable Solution

1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Ryan Carey

OTHER